Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has emerged as new drug target due to (a) its expression only during embryonic development but not in adult tissue, and (b) its amplification in cancer cells [1–5]. Here, MTHFD2 is linked to cancer.